Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gama Explorations, Inc. ( (TSE:SKNY) ) just unveiled an update.
LIR Life Sciences has signed a research and development services agreement with Indian CDMO Neuland Laboratories to develop and test novel cell-penetrating peptides that will support its transdermal GLP-1/GIP drug delivery platform for obesity treatment. The initial Phase 1 program, budgeted at about US$230,000 with potential expansion into later phases, is intended to advance preclinical evaluation, inform future clinical and commercial plans, and strengthen LIR’s ability to scale its peptide-based technology. In parallel, LIR has hired Vancouver-based Fairfax Partners for a three‑month, US$150,000 digital marketing and investor relations campaign, signaling an effort to raise the company’s profile among investors and the broader market as it progresses its obesity-focused pipeline.
More about Gama Explorations, Inc.
LIR Life Sciences Corp. is a biotechnology company focused on developing scalable and affordable obesity treatments using novel drug delivery methods. The company is advancing a transdermal patch and other delivery systems that mimic GLP-1, a hormone that regulates appetite and blood sugar, aiming to provide alternatives to injectable drugs and improve access, adherence, and cost-efficiency in both developed and emerging markets.
Average Trading Volume: 97,206
Technical Sentiment Signal: Buy
For a thorough assessment of SKNY stock, go to TipRanks’ Stock Analysis page.